M&A

News

Regeneron dials up in gene therapy with Decibel deal

Regeneron has agreed a $109 million deal to acquire Decibel Therapeutics and its early-stage gene therapy for a form of congenital deafness, several years after forming a

News

eureKING buys SCTbio to extend biomanufacturing push

Special purpose acquisition company (SPAC) eureKING has agreed a deal to buy SCTbio as part of a plan to build a contract manufacturing company specialising in biologic th

News

PacBio builds in short-read sequencing with $110m Apton buy

Gene sequencing specialist PacBio has reached an agreement to buy Apton Biosystems, boosting its position in short-read sequencing technology that has traditionally been d

News

EQRx's low-price drugs mission ends with Revolution buy

EQRx's pledge to disrupt the pharma pricing system started with a clarion call in 2020 but ended with a whimper today with an agreement to be taken over by Revolution Medi

News

After cutbacks, Biogen adds new drug with $7.3bn Reata buy

Biogen has turned to M&A to offset its recent troubles with pipeline failures and aborted product launches, agreeing to a $7.3 billion deal to acquire Reata Pharma.

News

AZ builds in genomic medicine with $1bn Pfizer deal

AstraZeneca's rare diseases unit Alexion has agreed to pay $1 billion to acquire Pfizer's early-stage gene therapy pipeline and enabling technologies - the company's first

Regeneron dials up in gene therapy with Decibel deal

eureKING buys SCTbio to extend biomanufacturing push

PacBio builds in short-read sequencing with $110m Apton buy

EQRx's low-price drugs mission ends with Revolution buy

After cutbacks, Biogen adds new drug with $7.3bn Reata buy

AZ builds in genomic medicine with $1bn Pfizer deal

Roche, Viking, and Syntis showcase obesity drug candidates

Discover a new era of healthcare panel engagement: Grounded ...

M&A

Editor's Picks